Interferon alpha induces a good molecular response in a patient with chronic eosinophilic leukemia (CEL) carrying the JAK2V617F point mutation.

Abstract	The JAK2 V617F point mutation is very rare in hypereosinophilic syndrome and/or chronic eosinophilic leukemia. Here we report on a patient with chronic eosinophilic leukemia and detectable JAK2 mutant clone, who achieved a good molecular response to interferon alpha-2a after 4 months of treatment. The molecular response correlated with only moderate haematological improvement.
Authors	G Helbig, B Stella-Holowiecka, M Majewski, M Lewandowska, J Holowiecki
Journal	Haematologica (Haematologica) Vol. 92 Issue 11 Pg. e118-9 (Nov 2007) ISSN: 1592-8721 [Electronic] Italy
PMID	18024388 (Publication Type: Case Reports, Journal Article)
Chemical References	Interferon alpha-2 Interferon-alpha Recombinant Proteins Janus Kinase 2
Topics	Chronic Disease Humans Hypereosinophilic Syndrome (drug therapy, genetics) Interferon alpha-2 Interferon-alpha (therapeutic use) Janus Kinase 2 (genetics) Male Middle Aged Point Mutation Recombinant Proteins Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!